Effects of beta-blockers on exercise performance in uncomplicated hypertension - ND

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-011156-21-IT

Enrollment

Registered

2011-09-02

Start date

2011-04-28

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non complicated arterial hypertension MedDRA version: 14.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disorders

Interventions

Trade Name: CONGESCOR*50CPR RIV 10MG Pharmaceutical Form: Coated tablet INN or Proposed INN: Bisoprolol Concentration unit: mg milligram(s) Concentration number: 10- Trade Name: ATENOLOLO TEVA*50CPR

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - patients with essential arterial hypertension (grade I and II) - age 40-70 years - ongoing efficacious anti-hypertensive treatment without beta blockers (PA =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: treatment with beta-blockers COPD controindications for the use of beta blockers arterial hypertension resistant to treatment, malignant or non essential.

Design outcomes

Primary

Measure	Time frame
Main Objective: Evaluation of peak VO2, maximal exercise capacity and tollerance in hypertensive patients with 2 treatments versus vasodilator drugs of routine treatment (ACE inhibitors, sartans, Calcium-antagonists, doxazosina).;Secondary Objective: Evaluation of the metabolic rate;Primary end point(s): difference in peak of VO2 (ml/Kg/min), exercise capacity and duration 10%	—

Countries

Italy

Contacts

Public ContactReferente OsSC

Centro Cardiologico

atanasio.nonis@ieo.it02 57 48 98 48

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026